Dactinomycin

Dactinomycin

SCHEMBL3845

Cc1c2oc3c(C)ccc(C(=O)N[C@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)c3nc-2c(C(=O)N[C@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)c(N)c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRB2 P62993 3/20 1.00
MAPT P10636 2/20 1.00
RECQL P46063 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
ABCB11 O95342 1/20 1.00
ALDH1A1 P00352 1/20 1.00
CYP3A4 P08684 1/20 1.00
ALOX15 P16050 1/20 1.00
PTGS1 P23219 1/20 1.00
CASP1 P29466 1/20 1.00
HTT P42858 1/20 1.00
BLM P54132 1/20 1.00
CASP7 P55210 1/20 1.00
KMT2A Q03164 1/20 1.00
HIF1A Q16665 1/20 1.00
DDR2 Q16832 1/20 1.00
NGLY1 Q96IV0 1/20 1.00
HSD17B10 Q99714 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dactinomycin SCHEMBL3844 1.00 GRB2 (1.00) GRB2MAPTRECQLSMN1; SMN2ABCB11
Dactinomycin SCHEMBL26186613 1.00 GRB2 (1.00) GRB2MAPTRECQLSMN1; SMN2ABCB11
Dactinomycin SCHEMBL13659669 1.00 GRB2 (1.00) GRB2MAPTRECQLSMN1; SMN2ABCB11
Dactinomycin SCHEMBL27304406 1.00 GRB2 (1.00) GRB2MAPTRECQLSMN1; SMN2ABCB11
Dactinomycin SCHEMBL6152 1.00 GRB2 (1.00) GRB2MAPTRECQLSMN1; SMN2ABCB11
Dactinomycin SCHEMBL19770615 1.00 GRB2 (1.00) GRB2MAPTRECQLSMN1; SMN2ABCB11
Dactinomycin SCHEMBL6939686 1.00 GRB2 (1.00) GRB2MAPTRECQLSMN1; SMN2ABCB11
Dactinomycin SCHEMBL28168861 0.99 GRB2 (0.99) GRB2MAPTRECQLSMN1; SMN2ABCB11
Dactinomycin SCHEMBL2790145 0.99 GRB2 (0.99) GRB2MAPTRECQLSMN1; SMN2ABCB11
Dactinomycin SCHEMBL28161860 0.99 GRB2 (0.98) GRB2MAPTRECQLSMN1; SMN2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 139099 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
EP-4747263-A1 LIPID NANOPARTICLES AND USES THEREOF University of Connecticut (US) 2026-05-27 EP claimed
CN-122075497-A Use of NLRP3 agonist for tumor treatment 2026-05-26 CN claimed
US-20260137636-A1 TUMOR-TARGETING THIOCOLCHICINE NANOEMULSION SMITH HENRY (US) 2026-05-21 US claimed
WO-2026107377-A1 PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL KARANICOLAS JOHN (US) 2026-05-21 WO claimed
US-20260137700-A1 PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE SK BIOPHARMACEUTICALS CO LTD (KR) 2026-05-21 US claimed
US-20260137650-A1 MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) 11949098 CANADA INC (CA) 2026-05-21 US claimed
WO-2026105121-A1 ANTICANCER FORMULATIONS AND USES THEREOF INTRAGEL THERAPEUTICS LTD. (IL) 2026-05-21 WO claimed
EP-4743490-A1 HUMANIZED ANTI-CD7 ANTIBODY Christian-Albrechts-Universität zu Kiel (DE) 2026-05-20 EP claimed
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
US-4717563-A 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs A. H. ROBINS COMPANY, INC. (US) 1988-01-05 US claimed
EP-0240180-A1 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamides and thiobenzamides in the alleviation of emesis caused by non-platinum anticancer drugs SYNTHELABO (FR) 1987-10-07 EP claimed
EP-0237281-A1 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamide-N-oxides in the control of emesis caused by anticancer drugs SYNTHELABO (FR) 1987-09-16 EP claimed
EP-0222425-A2 Brain-specific drug delivery UNIVERSITY OF FLORIDA (US) 1987-05-20 EP claimed
EP-0218300-A2 Brain-specific drug delivery UNIVERSITY OF FLORIDA (US) 1987-04-15 EP claimed
EP-0213523-A2 Pharmaceutical compositions containing acylated phospholipids BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1987-03-11 EP claimed
US-4622218-A Testicular-specific drug delivery UNIVERSITY OF FLORIDA (US) 1986-11-11 US claimed
EP-0178624-A2 Liposomes from synthetic lipids CIBA-GEIGY AG (CH) 1986-04-23 EP claimed
EP-0110955-A1 BRAIN-SPECIFIC DRUG DELIVERY. UNIV FLORIDA (US) 1984-06-20 EP claimed
WO-1983003968-A1 BRAIN-SPECIFIC DRUG DELIVERY UNIVERSITY OF FLORIDA (US) 1983-11-24 WO claimed